Hau(p)t-sache schön: Neue Subdisziplin auf dem Vormarsch

Prof. Dr. med. Bernd Kleine-Gunk und Univ.-Prof. Dr. Dr. med. Johannes Huber Seiten 6-10

  1. Busch P. Historische Entwicklung der Kosmetik. In: Umbach W (Hrsg) Kosmetik, 2. Aufl. Georg Thieme Verlag 1995; Stuttgart, S. 1-9.
  2. Uitto J. Understanding premature skin aging. N Engl J Med 1997; 337:1463-1465.
  3. Wlaschek M, Tantcheva-Poor I, Naderi L, Ma W, Schneider LA, Razi-Wolf Z, Schuller J, Scharfetter-Kochanek K. Solar UV irradiation und dermal photo-aging. J Photochem Photobiol 2001; B 63:41-51.
  4. Lavker RM. Cutaneous aging: chronologic versus photo-aging. In: Gilchrest BA (ed) Photodamage. Blackwell Science 1995; Cambridge, Mass, 123-135.
  5. Uitto J, Fazio MJ, Olsen DR. Molecular mechanism of cutaneous aging. J Am Acad Dermatol 1998; 21:614-622.
  6. Huber J, Kleine-Gunk B. Ästhetische Endokrinologie - die dermatologische Bedeutung der Sexualsteroide Privatarzt Gynäkologie 2012; 12:38-42.
  7. Philips TJ, Demicay Z, Sahu M. Hormonal effects on skin aging. Clin Geriatr Med 2001; 17: 661-672.
  8. Rabe T, Zouboulis C.C, Kleine-Gunk B, Huber J. Ästhetische Endokrinologie erschienen in Rabe et al. Seminarbuch in Gynäkologischer Endokrinologie 2013; Band 2.
  9. Sator P-G, Schmidt JB, Tabe T, Zouboulis CC. Skin aging and sex hormones in women – Clinical perspectives for intervention by hormonal replacement therapy. Exp Dermatol 2004; 13(Suppl4): 36-40.
  10. Brincat MP. Hormone replacement therapy and the skin. Maturitas 2000; 35: 107-117.
  11. Henry F, Pierard-Franchimont C, Cauwenbergh G, Pierard GE. Age-related changes in facial skin contours and rheology. J Am Geriatr Soc 1997; 45:220-222.
  12. Dunn LB, Damesyn M, Moore AA et al. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES). Arch Dermatol 1997; 133: 339-342.
  13. Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of skin aging with topical estrogens. Int J Dermatol 1996; 35:669-674.
  14. Creidi P, Faivre B, Agache P et al. Effect of a conjugated oestrogen (Premarin) cream on ageing facial Skin. A comparative study with a placebo cream. Maturitas 1994; 19: 211-223.
  15. Huber J, Gruber C. Immunological and dermatological impact of progesterone. Gynecol Endocrinol 2001; 15:18-21.
  16. Lahmann C, Bergemann J, Harrison G. Young AR. Matrix metalloproteinase-1 and skin ageing in smokers. Lancet 2001; 357:935-936.
  17. Gruber DM, Sator MO, Joura EA et al. Topical cyproterone acetate treatment in women with acne. Arch Dermatol 1998; 134: 459-63.
  18. Kleine-Gunk. Hormone für die Schönheit – Kosmetische Effekte topischer Steroide, Haut 2008; 1:6-9.
  19. Gruber DM, Sator MO, Kirchengast S, Joura EA, Huber JC. Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women. Maturitas 1998; 29:253-9.
  20. Kleine-Gunk B, Mrakovic D. Ästhetische Endokrinologie - Mit topischen Steroidhormonen kosmetische Effekte erzielen, Frauenarzt 2005; 46:202-208.

    Ernährung und Lebensstil in der Schwangerschaft

    Dr. Brigitte Brands und Univ.-Prof. Dr. med. Dr. med. habil. Berthold Koletzko
    Seiten 18-21

    1. Beyerlein A, Schiessl B et al. Associations of gestational weight loss with birth-related outcome: a retrospective cohort study. BJOG 2011; 118(1): 55-61.
    2. Butte NF. Energy requirements during pregnancy and consequences of deviations from requirement on fetal outcomes. Nestle Nutr Workshop Ser Pediatr Program 2005; 55: 49-67; discussion 67-71.
    3. Butte NF and King JC. Energy requirements during pregnancy and lactation. Public Health Nutr 2005; 8(7A): 1010-1027.
    4. Cantwell R, Clutton-Brock T et al. Saving Mothers Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 Suppl1:1-203.
    5. Crane JM, White J et al. The effect of gestational weight gain by body mass index on maternal and neonatal outcomes. J Obstet Gynaecol Can 2009; 31(1): 28-35.
    6. De-Regil LM, Fernandez-Gaxiola AC et al. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010; (10): CD007950.
    7. Dietz PM, Callaghan WM et al. Combined effects of prepregnancy body mass index and weight gain during pregnancy on the risk of preterm delivery. Epidemiology 2006 17(2): 170-177.
    8. EFSA Panel on Dietetic Products, N. a. A. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal 2010; 8(3): 1461-1368.
    9. EUROCAT. Special Report: A Review of Environmental Risk Factors for Congenital Anomalies. Belfast 2004; EUROCAT Central Registry, University of Ulster.
    10. Goldberg GR. Nutrition in pregnancy: the facts and fallacies. Nurs Stand 2003; 17(19): 39-42.
    11. Goldenberg RL and Culhane JF. Low birth weight in the United States. Am J Clin Nutr 2007; 85(2): 584S-590S.
    12. Han Z, Mulla S et al. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. Int J Epidemiol 2011; 40(1): 65-101.
    13. IOM. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington D.C. 1997; The National Academies Press.
    14. IOM. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, D.C. 1998; National Academy Press.
    15. IOM. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. Washington D.C. 2000; The National Academies Press.
    16. IOM. Dietary Reference Intakes for Vitamin A, Vitamin K, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. Washington D.C. 2001; National Academies Press.
    17. IOM. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. Washington D.C. 2005; National Academies Press.
    18. IOM. Weight gain during pregnancy: Reexamining the Guidelines. Washington, D.C. 2009; The National Academies Press.
    19. IOM. Dietary Reference Intakes for Calcium and Vitamin D. Washington, D.C. 2011; The National Academies Press.
    20. Koletzko B, Cetin I et al. Dietary fat intakes for pregnant and lactating women. Br J Nutr 2007; 98(5): 873-877.
    21. Lam PK, Torfs CP et al. A low pregnancy body mass index is a risk factor for an offspring with gastroschisis. Epidemiology 1999; 10(6): 717-721.
    22. McDonald SD, Han Z et al. Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses. BMJ 2010; 341: c3428.
    23. NICE. Weight management before, during and after pregnancy. National Institute for Health and Care Excellence London. Nice Public Health Guidance 2010:27.
    24. Nutrition SACo. Dietary Recommendations for Energy; 2011.
    25. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr 2007; 85(1): 285S-288S.
    26. Poston L. Intergenerational transmission of insulin resistance and type 2 diabetes. Prog Biophys Mol Biol 2011; 106(1): 315-322.
    27. Prentice AM and Goldberg GR. Energy adaptations in human pregnancy: limits and long-term consequences. Am J Clin Nutr 2000; 71(5 Suppl): 1226S-1232S.
    28. Stothard KJ, Tennant PW et al. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009: 301(6): 636-650.
    29. Viswanathan M, Siega-Riz AM et al. Outcomes of maternal weight gain. Evid Rep Technol Assess (Full Rep) 2008 (168): 1-223.
    30. WHO. Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination. A guide for programme managers. 2007.
    31. WHO/UNU-Expert-Consultation. Human energy requirements: report of a joint FAO/ WHO/UNU Expert Consultation. Food Nutr Bull 2005; 26(1): 166.
    32. Yu CK, Teoh TG et al. Obesity in pregnancy. BJOG 2006; 113(10): 1117-1125.
    33. Zhang X, Decker A et al. How big is too big? The perinatal consequences of fetal macrosomia. Am J Obstet Gynecol 2008; 198(5): 517 e511-516.
    34. Zimmermann MB. The effects of iodine deficiency in pregnancy and infancy. Paediatr Perinat Epidemiol 2012; 26 Suppl 1: 108-117.

    Simulation in der Geburtshilfe

    Prof. Dr. med. Franz Kainer
    Seiten 22-24

    1. Draycott T et al. Does training in obstetric emergencies improve neonatal outcome? BJOG 2006;113:177-182.
    2. Draycott T et al. Improving neonatal outcome through practical shoulder dystocia training. Obstet Gynaecol 2008; 112:14-20.
    3. Hammoud MM, Nuthalapaty FS, Goepfert  AR, et al. To the point: medical education review of the role of simulators in surgical training. American Journal of Obstetrics and Gynecology 2008.
    4. Jude DC, Gilbert GG, Magrane D. Simulation training in the obstetrics and gynecology clerkship. Am J Obstet Gynecol 2006; 195:1489-92.
    5. Pratt S et al. Impact of CRM-based training on obstetric outcomes and clinician´s patient safety attitudes. Jt Comm J Qual Patient Safety 2007; 33:720-725.
    6. Rattner Gelbart, R. The king´s midwife: A history and mystery of Madame du Coudray; 1998.
    7. St. Pierre M, Breuer G(Herausgeber). Simulation in der Medizin: Grundlegende Konzepte - Klinische Anwendung; Springer Verlag 2013.

    CME-Fortbildung: Hereditäres Mamma- und Ovarialkarzinom

    PD Dr.med. Nina Ditsch und Prof. Dr. rer. nat. Alfons Meindl
    Seiten 27-34

    1. Meindl A, Hellebrand H et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 470-474.
    2. Pelttari LM, Heikkinen T et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mut online 2011; doi: 10.1093/hmg/ddr229.
    3. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present and future. Annu Rv Genomics Hum Genet 2008; 9: 321-345.
    4. Ripperger T, Gadzicki D, Meindl A et al. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 2009; 17: 722-731.
    5. Smith P, Mc Guffog L et al. for the Breast Cancer Susceptibility Collaboration. A genome wide linkage - search for breast cancer susceptibility genes. Genes Chromosomes Cancer 2006; 45: 646-655.
    6. Hunter DJ, Yeager M et al. A genome wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870-874.
    7. Easton DF, Pooley KA et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093.
    8. Metzker ML. Sequencing technologies: the next generation. Nat Rev Genet 2010; 11: 31-46.
    9. King MC, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
    10. Gómez García EB, Oosterwijk JC. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 2009; 11: R8.
    11. Miki Y, Swensen J et al. A strong candidate for the breast and ovarian cancer – susceptibility gene BRCA 1. Science 1994; 266: 66-71.
    12. Antoniou AC, Pharoah PD et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005; 42: 602-603.
    13. Antoniou AC, Pharoah PD et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J Hum Genet 2003; 72: 1117-1130.
    14. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA 1 and BRCA 2 mutation carriers: results from the Consortiumof Investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134.
    15. Gadzicki D, Schlegelberger B. Histopathological criteria and selection algorithms for BRCA1 genetic testing. Cancer Genet Cytogenet 2009; 189: 105.
    16. Rhiem K, Engel C, Graeser M et al. The risk of contralateral breast cancer in patients fromBRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14: R156.
    17. Brekelmans CTM, Klijn JGM. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA 2, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007; 43: 867-876.
    18. Hruban RH, Canto M et al. Update on familial pancreatic cancer. Adv Surg 2010; 44: 293-311.
    19. Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA 1 and BRCA 2 mutation carriers. BR J Cancer 2012; 107: 2005-2009.
    20. Thorne H, Willems AJ, Niedermayr E et al. Decreased prostate cancer-specific survival of men with BRCA 2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011; 4 (7): 1002-1010.
    21. Mitra AV, Bancroft EK et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects agresssive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2001; 107: 28-39.
    22. Robertson L, Hanson H, Seal S, et al. BRCA 1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 2012; 106: 1234-1238.
    23. Hendrick RE, Pisano ED et al. Comparison of acquisition parameters and breast dose in digital mammography and screenfilm mammography in the American Colllege of Radiology Imaging Network digital mammographic imaging screening trial. Am J Roentgenol 2010; 194: 362-369.
    24. Sim LS, Hendriks JH et al. US correlation for MRI-detected breast lesions in women with familial risk of breast cancer. Clin Radiol 2005; 60: 801-806.
    25. Kuhl C, Weigel S et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010; 28: 1450-1457.
    26. Riedl CC, Ponhold L et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance ofwomen at high risk for breast cancer. Clin Cancer Res 2007; 13: 6144-6152.
    27. Warner E, Causer P et al. Improvement in DCIS detection rates by MRI over time in a high risk breast screening study. Breast 2011b; 17: N1: 9-17.
    28. Warner E, Hill K et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011a; 29: 1664-1669.
    29. Sardanelli F, Boetes C et al. Magnetic resonance imaging of the breast. Recommendation from the EUSOM Aworking group. Eur J Cancer 2010; 46: 1296-1316.
    30. Isern AE, Ringberg A et al. Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J Plast Reconstr Aesthet Surg 2008; 61: 1177-1187.
    31. Domchek SM, Friebel TM et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.
    32. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
    33. Garcia-Etienne CA, Borgen PI. Update on the indications for nipple-sparingmastectomy. J Support Oncol 2006; 4: 225-230.
    34. Heitmann C, Schmutzler R, Richter-Heine I et al. Brustrekonstruktionen durch Eigengewebe bei familiärer Disposition (BRCA 1/2-Mutationsträgerinnen). Senologie 2009; 6: 203-209.
    35. Finch A, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296: 185-192.
    36. Domchek SM, Friebel TM et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.
    37. Eisen A, Lubinski J, Klijn et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2mutation carriers: an international case-control study. J Clin Oncol 2005; 23: 7491-7496.
    38. Gabriel CA, Domchek S M et al. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer 2009; 8: 23-28
    39. Sestak I, Cuzick J. Preventive therapy for breast cancer. Curr Oncol Rep. 2012; Dec; 14(6): 568-573.
    40. King MC, Fisher B. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA 1 and BRCA 2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-2256.
    41. Wen J, Li R, Lu Y, Shupnik MA. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 2009; 28: 575-586.
    42. Coyle YM. Lifestyle genes and cancer. Methods Mol Biol 2009; 472: 25-56.
    43. Ghadirian P, Narod S et al. Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity. Breast Cancer Res Treat 2009; 117: 417-422.
    44. Nkondjock A, Ghadirian P. Diet quality and BRCA-associated breast cancer risk. Breast Cancer Res Treat 2007; 103: 361-369.
    45. Peel JB, Blair SN et al. A prospective study of cardiorespiratory fitness and breast cancer mortality. Med Sci Sports Exerc 2009; 41: 742-748.
    46. Turnbull C, Eeles R et al. Radiotherapy and genetic predisposition to breast cancer. Clin Oncol (R Coll Radiol) 2006; 18: 257-267.
    47. Pierce L. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. Semin Radiat Oncol 2002; 12: 352-361.
    48. Kriege M, Brekelmans CT et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
    49. Pierce LJ, Weber BL et al. Ten year multi institutional results of breast conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 124: 2437-2443.
    50. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl) 2012; 8: 543-555.
    51. Graeser M, Engel Ch et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 1-6.
    52. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105 (11): 812-822.
    53. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. FamCancer 2006; 5: 135-142.
    54. Liedtke C, Mazouni C et al. Response to neoadjuvant therapy and long-termsurvival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
    55. Byrski T, Narod SA et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115: 359-363.
    56. Imyanitov EN. Breast cancer therapy for BRCA 1 carriers: moving towards platinum standard? Hered Cancer Clin Pract 2009; 7: 8.
    57. Wysocki PJ, Mackiewicz A et al. Primary resistance to docetaxel-based chemotherapy inmetastatic breast cancer patients correlates with a high frequency of BRCA1mutations. Med SciMonit 2008; 14: SC7-10.
    58. Byrski T, Gronwald J et al. Pathologic complete response rates in young women with BRCA1-postive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
    59. Bryant HE, Helleday T et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 913-917.
    60. Daemen A, Wolf DM, Korkola JE et al. Cross-platform pathway-based analysis identifie markers of response to the PARP inhibitor olaparib. Brest Cancer Res Treat 2012; 135: 505-517.
    61. Plummer R, Calvert H et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-7923.
    62. Tutt A, Robson M et al. Oral poly (ADP-ribose) polymerase inhibitor olabarip in patients with BRCA 1 or BRCA 2 mutations and advanced breast cancer: a proof of concept trial. Lancet 2010; 376: 235-244.
    63. Rhiem K, Engel C, Graeser M et al. The risk of contralateral breast cancer in patient fromBRCA1/2 negative high risk families as compared to patients fromBRCA1 or BRCA 2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14: R156.


      von Dr. med. Verena Henninger, Dr. med. Katharina Rall und Prof. Dr. med. Sara Y. Brucker
      Seiten 38 bis 43

      1. AWMF, S1-Leitlinie Gynäkologie 015/052: Weibliche genitale Fehlbildungen. Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). 07/2010.
      2. Baltzer J and Zander J. Primary squamous cell carcinoma of the neovagina. Gynecol Oncol 1989; 35 (1): 99-103.
      3. Bean EJ, Mazur T, Robinson AD. Mayer-Rokitansky-Kuster-Hauser syndrome: sexuality, psychological effects, and quality of life. J Pediatr Adolesc Gynecol 2009; 22 (6): 339-346.
      4. Belleannee G, Brun JL, Trouette H, Mompart JP, Goussot JF, Brun G and de Mascarel A. Cytologic findings in a neovagina created with Vecchietti's technique for treating vaginal aplasia. Acta Cytol 1998; 42 (4): 945-948.
      5. Borruto F, Mayer-Rokitansky-Kuster Syndrome: Vecchietti's personal series. Clin Exp Obstet Gynecol 1992; 19 (4): 273-274.
      6. Brucker SY, Gegusch M, Zubke W, Rall K, Gauwerky JF, and Wallwiener D. Neovagina creation in vaginal agenesis: development of a new laparoscopic Vecchietti-based procedure and optimized instruments in a prospective comparative interventional study in 101 patients. Fertil Steril 2008; 90 (5): 1940-1952.
      7. Brucker SY, Zubke W., Wallwiener D. Optimierung der laparoskopisch assistierten Neovagina-Anlage durch neue Applikationsinstrumente inklusive einem neuen mechanischen Spannapparat. Geburtshilfe Frauenheilkd 2004; 64: 70-75.
      8. Demirel F, Kara O, and Esen I. Inguinal ovary as a rare diagnostic sign of Mayer-Rokitansky-Kuster-Hauser syndrome. J Pediatr Endocrinol Metab 2012; 25 (3-4): 383-386.
      9. Deniz N, Perk H, Serel T, Kosar A, Ozsoy MH, and Arslan M, Urethral coitus and urinary incontinence in a case of Mayer-Rokitansky syndrome: an alternative surgical procedure. Eur J Obstet Gynecol Reprod Biol 2002; 103 (1): 95-96.
      10. Edmonds DK, Congenital malformations of the genital tract. Obstet Gynecol Clin North Am 2000; 27 (1): 49-62.
      11. Fedele L, Bianchi S, Berlanda N, Fontana E, Raffaelli R, Bulfoni A, and Braidotti P. Neovaginal mucosa after Vecchietti's laparoscopic operation for Rokitansky syndrome: structural and ultrastructural study. Am J Obstet Gynecol 2006; 195 (1): 56-61.
      12. Frank R, The formation of an artificial vagina without operation. Am J Obstet Gynecol 1938; 35: 1045-1055.
      13. Frega A, Scirpa P, Sopracordevole F, Biamonti A, Bianchi P, De Sanctis L, Lorenzon L, Pacchiarotti A, French D, and Moscarini M. Impact of human papillomavirus infection on the neovaginal and vulval tissues of women who underwent surgical treatment for Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 2011; 96 (4): 969-973.
      14. Gauwerky JF, Wallwiener D, and Bastert G. An endoscopically assisted technique for construction of a neovagina. Arch Gynecol Obstet 1992; 252 (2): 59-63.
      15. Gauwerky JF, Wallwiener D, and Bastert G. Endoscopically assisted construction of a neovagina--surgical technique and experience. Geburtshilfe Frauenheilkd 1993; 53 (4): 261-264.
      16. Janisch H, Riss P, Schieder K, and Rogan AM. Vecchietti's operation for the formation of a neovagina: technic and results. Geburtshilfe Frauenheilkd 1984; 44 (1): 53-55.
      17. K. Rall1 MW, I. Rießen1, S. Zipfel1, D. Wallwiener1, S. Brucker1, Optimierung von Aufklärung, Betreuung und Compliance bei Patientinnen mit seltenem gynäkologischen Krankheitsbild. Geburtshilfe Frauenheilkd 2008; 68 (11): 1102-1105.
      18. Laufer MR, Congenital absence of the vagina: in search of the perfect solution. When, and by what technique, should a vagina be created? Curr Opin Obstet Gynecol 2002; 14(5): 441-444.
      19. Heinz M. Konservatives Vorgehen bei Vaginalaplasie - Medizinische und psychologische Aspekte. Frauenarzt 2006; 47 (1): 34-37.
      20. Marsh CA, Will MA, Smorgick N, Quint EH, Hussain H, and Smith YR, Uterine remnants and pelvic pain in females with Mayer-Rokitansky-Kuster-Hauser syndrome. J Pediatr Adolesc Gynecol 2013; 26 (3): 199-202.
      21. Oppelt PG, Lermann J, Strick R, Dittrich R, Strissel P, Rettig I, Schulze C, Renner SP, Beckmann MW, Brucker S, Rall K, Mueller A. Malformations in a cohort of 284 women with Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH). Reprod Biol Endocrinol 2012; 10: 57.
      22. Papa G, Andreotti M, Giannubilo SR, Cesari R, Cere I, and Tranquilli AL. Case report and surgical solution for a voluminous uterine leiomyoma in a woman with complicated Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 2008; 90 (5): 2014 e5-6.
      23. Perez-Medina T, Pereira A, de Argila N, Folgueira G, Iglesias E. Follow-up in women with vaginal agenesis after laparoscopic creation of neovagina. J Minim Invasive Gynecol 2013; 20 (1): 85-89.
      24. Peters WA 3rd and Uhlir JK. Prolapse of a neovagina created by self-dilatation. Obstet Gynecol 1990; 76 (5 Pt 2): 904-906.
      25. Rall K, Barresi G, Wallwiener D, Brucker SY, and Staebler A, Uterine rudiments in patients with Mayer-Rokitansky-Kuster-Hauser syndrome consist of typical uterine tissue types with predominantly basalis-like endometrium. Fertil Steril 2013; 99 (5): 1392-1399.
      26. Rall KB, S., Die drei A der Vaginalaplasie - kein differentialdiagnostisches Chamäleon. Frauenarzt 2007; 48: 940-948.
      27. Steiner E, Woernle F, Kuhn W, Beckmann K, Schmidt M, Pilch H, Knapstein PG. Carcinoma of the neovagina: case report and review of the literature. Gynecol Oncol 2002; 84 (1): 171-175.
      28. van Troost MH. Laparoscopic removal of a large uterine leiomyoma in a patient with Mayer-Rokitansky-Küster-Hauser-syndrome: a case report. Gynecol Surg 2012; 9: 445-447.
      29. Vecchietti G. Creation of an artificial vagina in Rokitansky-Kuster-Hauser syndrome. Attual Ostet Ginecol 1965; 11 (2): 131-147.